Trial Profile
A pilot study evaluating procedural success and clinical utility of the Fantom bioresorbable scaffold in the patients with acute heart attacks called ST-segment elevated myocardial infarction (STEMI)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Antiplatelets
- Indications Coronary artery restenosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms FANTOM STEMI
- 18 Oct 2020 Trial design presented at the 32nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 05 Oct 2018 New trial record
- 25 Sep 2018 Trial design presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics. 10 STEMI patients were enrolled till date. Results are anticipated bu August 2018. Full conclusions expected after final analysis of results.